Global Neoantigen Vaccine Market 2021 by Company, Regions, Type and Application, Forecast to 2026

Description

The Neoantigen Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Neoantigen Vaccine size is estimated to be USD  million in 2026 from USD  million in 2020, with a change  % between 2020 and 2021. The global Neoantigen Vaccine market size is expected to grow at a CAGR of  % for the next five years.

Market segmentation
Neoantigen Vaccine market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
    Personalized Vaccine
    Off-the shelf Vaccine

Market segment by Application, can be divided into
    Lung Cancer
    Melanoma Cancer
    Gastrointestinal Cancer
    Brain Cancer
    Others

Market segment by players, this report covers
    Pfizer
    Merck & Co Inc
    Eli Lilly and Company
    BioNTech
    Roche Holding AG
    OSE Immunotherapeutics
    Gritstone Bio
    Moderna
    Avidea Technologies
    Vaccibody AS
    Agenus Inc
    Novogene
    ZIOPHARM Oncology
    ISA Pharmaceuticals
    BrightPath Biotherapeutics
    Vaximm AG
    Medigene AG
    Genocea Biosciences Inc
    Advaxis
    Nouscom

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
    South America (Brazil, Argentina, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Neoantigen Vaccine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Neoantigen Vaccine, with revenue, gross margin and global market share of Neoantigen Vaccine from 2019 to 2021.
Chapter 3, the Neoantigen Vaccine competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Neoantigen Vaccine market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Neoantigen Vaccine research findings and conclusion, appendix and data source.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Neoantigen Vaccine
    1.2 Classification of Neoantigen Vaccine by Type
        1.2.1 Overview: Global Neoantigen Vaccine Market Size by Type: 2020 Versus 2021 Versus 2026
        1.2.2 Global Neoantigen Vaccine Revenue Market Share by Type in 2020
        1.2.3 Personalized Vaccine
        1.2.4 Off-the shelf Vaccine
    1.3 Global Neoantigen Vaccine Market by Application
        1.3.1 Overview: Global Neoantigen Vaccine Market Size by Application: 2020 Versus 2021 Versus 2026
        1.3.2 Lung Cancer
        1.3.3 Melanoma Cancer
        1.3.4 Gastrointestinal Cancer
        1.3.5 Brain Cancer
        1.3.6 Others
    1.4 Global Neoantigen Vaccine Market Size & Forecast
    1.5 Global Neoantigen Vaccine Market Size and Forecast by Region
        1.5.1 Global Neoantigen Vaccine Market Size by Region: 2016 VS 2021 VS 2026
        1.5.2 Global Neoantigen Vaccine Market Size by Region, (2016-2021)
        1.5.3 North America Neoantigen Vaccine Market Size and Prospect (2016-2026)
        1.5.4 Europe Neoantigen Vaccine Market Size and Prospect (2016-2026)
        1.5.5 Asia-Pacific Neoantigen Vaccine Market Size and Prospect (2016-2026)
        1.5.6 South America Neoantigen Vaccine Market Size and Prospect (2016-2026)
        1.5.7 Middle East and Africa Neoantigen Vaccine Market Size and Prospect (2016-2026)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 Neoantigen Vaccine Market Drivers
        1.6.2 Neoantigen Vaccine Market Restraints
        1.6.3 Neoantigen Vaccine Trends Analysis

2 Company Profiles
    2.1 Pfizer
        2.1.1 Pfizer Details
        2.1.2 Pfizer Major Business
        2.1.3 Pfizer Neoantigen Vaccine Product and Solutions
        2.1.4 Pfizer Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.1.5 Pfizer Recent Developments and Future Plans
    2.2 Merck & Co Inc
        2.2.1 Merck & Co Inc Details
        2.2.2 Merck & Co Inc Major Business
        2.2.3 Merck & Co Inc Neoantigen Vaccine Product and Solutions
        2.2.4 Merck & Co Inc Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.2.5 Merck & Co Inc Recent Developments and Future Plans
    2.3 Eli Lilly and Company
        2.3.1 Eli Lilly and Company Details
        2.3.2 Eli Lilly and Company Major Business
        2.3.3 Eli Lilly and Company Neoantigen Vaccine Product and Solutions
        2.3.4 Eli Lilly and Company Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.3.5 Eli Lilly and Company Recent Developments and Future Plans
    2.4 BioNTech
        2.4.1 BioNTech Details
        2.4.2 BioNTech Major Business
        2.4.3 BioNTech Neoantigen Vaccine Product and Solutions
        2.4.4 BioNTech Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.4.5 BioNTech Recent Developments and Future Plans
    2.5 Roche Holding AG
        2.5.1 Roche Holding AG Details
        2.5.2 Roche Holding AG Major Business
        2.5.3 Roche Holding AG Neoantigen Vaccine Product and Solutions
        2.5.4 Roche Holding AG Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.5.5 Roche Holding AG Recent Developments and Future Plans
    2.6 OSE Immunotherapeutics
        2.6.1 OSE Immunotherapeutics Details
        2.6.2 OSE Immunotherapeutics Major Business
        2.6.3 OSE Immunotherapeutics Neoantigen Vaccine Product and Solutions
        2.6.4 OSE Immunotherapeutics Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.6.5 OSE Immunotherapeutics Recent Developments and Future Plans
    2.7 Gritstone Bio
        2.7.1 Gritstone Bio Details
        2.7.2 Gritstone Bio Major Business
        2.7.3 Gritstone Bio Neoantigen Vaccine Product and Solutions
        2.7.4 Gritstone Bio Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.7.5 Gritstone Bio Recent Developments and Future Plans
    2.8 Moderna
        2.8.1 Moderna Details
        2.8.2 Moderna Major Business
        2.8.3 Moderna Neoantigen Vaccine Product and Solutions
        2.8.4 Moderna Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.8.5 Moderna Recent Developments and Future Plans
    2.9 Avidea Technologies
        2.9.1 Avidea Technologies Details
        2.9.2 Avidea Technologies Major Business
        2.9.3 Avidea Technologies Neoantigen Vaccine Product and Solutions
        2.9.4 Avidea Technologies Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.9.5 Avidea Technologies Recent Developments and Future Plans
    2.10 Vaccibody AS
        2.10.1 Vaccibody AS Details
        2.10.2 Vaccibody AS Major Business
        2.10.3 Vaccibody AS Neoantigen Vaccine Product and Solutions
        2.10.4 Vaccibody AS Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.10.5 Vaccibody AS Recent Developments and Future Plans
    2.11 Agenus Inc
        2.11.1 Agenus Inc Details
        2.11.2 Agenus Inc Major Business
        2.11.3 Agenus Inc Neoantigen Vaccine Product and Solutions
        2.11.4 Agenus Inc Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.11.5 Agenus Inc Recent Developments and Future Plans
    2.12 Novogene
        2.12.1 Novogene Details
        2.12.2 Novogene Major Business
        2.12.3 Novogene Neoantigen Vaccine Product and Solutions
        2.12.4 Novogene Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.12.5 Novogene Recent Developments and Future Plans
    2.13 ZIOPHARM Oncology
        2.13.1 ZIOPHARM Oncology Details
        2.13.2 ZIOPHARM Oncology Major Business
        2.13.3 ZIOPHARM Oncology Neoantigen Vaccine Product and Solutions
        2.13.4 ZIOPHARM Oncology Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.13.5 ZIOPHARM Oncology Recent Developments and Future Plans
    2.14 ISA Pharmaceuticals
        2.14.1 ISA Pharmaceuticals Details
        2.14.2 ISA Pharmaceuticals Major Business
        2.14.3 ISA Pharmaceuticals Neoantigen Vaccine Product and Solutions
        2.14.4 ISA Pharmaceuticals Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.14.5 ISA Pharmaceuticals Recent Developments and Future Plans
    2.15 BrightPath Biotherapeutics
        2.15.1 BrightPath Biotherapeutics Details
        2.15.2 BrightPath Biotherapeutics Major Business
        2.15.3 BrightPath Biotherapeutics Neoantigen Vaccine Product and Solutions
        2.15.4 BrightPath Biotherapeutics Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.15.5 BrightPath Biotherapeutics Recent Developments and Future Plans
    2.16 Vaximm AG
        2.16.1 Vaximm AG Details
        2.16.2 Vaximm AG Major Business
        2.16.3 Vaximm AG Neoantigen Vaccine Product and Solutions
        2.16.4 Vaximm AG Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.16.5 Vaximm AG Recent Developments and Future Plans
    2.17 Medigene AG
        2.17.1 Medigene AG Details
        2.17.2 Medigene AG Major Business
        2.17.3 Medigene AG Neoantigen Vaccine Product and Solutions
        2.17.4 Medigene AG Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.17.5 Medigene AG Recent Developments and Future Plans
    2.18 Genocea Biosciences Inc
        2.18.1 Genocea Biosciences Inc Details
        2.18.2 Genocea Biosciences Inc Major Business
        2.18.3 Genocea Biosciences Inc Neoantigen Vaccine Product and Solutions
        2.18.4 Genocea Biosciences Inc Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.18.5 Genocea Biosciences Inc Recent Developments and Future Plans
    2.19 Advaxis
        2.19.1 Advaxis Details
        2.19.2 Advaxis Major Business
        2.19.3 Advaxis Neoantigen Vaccine Product and Solutions
        2.19.4 Advaxis Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.19.5 Advaxis Recent Developments and Future Plans
    2.20 Nouscom
        2.20.1 Nouscom Details
        2.20.2 Nouscom Major Business
        2.20.3 Nouscom Neoantigen Vaccine Product and Solutions
        2.20.4 Nouscom Neoantigen Vaccine Revenue, Gross Margin and Market Share (2019-2021)
        2.20.5 Nouscom Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Neoantigen Vaccine Revenue and Share by Players (2019-2021)
    3.2 Market Concentration Rate
        3.2.1 Top 3 Neoantigen Vaccine Players Market Share
        3.2.2 Top 10 Neoantigen Vaccine Players Market Share
        3.2.3 Market Competition Trend
    3.3 Neoantigen Vaccine Players Head Office, Products and Services Provided
    3.4 Mergers & Acquisitions
    3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type
    4.1 Global Neoantigen Vaccine Revenue and Market Share by Type (2016-2021)
    4.2 Global Neoantigen Vaccine Market Forecast by Type (2021-2026)

5 Market Size Segment by Application
    5.1 Global Neoantigen Vaccine Revenue Market Share by Application (2016-2021)
    5.2 Neoantigen Vaccine Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application
    6.1 North America Neoantigen Vaccine Revenue by Type (2016-2026)
    6.2 North America Neoantigen Vaccine Revenue by Application (2016-2026)
    6.3 North America Neoantigen Vaccine Market Size by Country
        6.3.1 North America Neoantigen Vaccine Revenue by Country (2016-2026)
        6.3.2 United States Neoantigen Vaccine Market Size and Forecast (2016-2026)
        6.3.3 Canada Neoantigen Vaccine Market Size and Forecast (2016-2026)
        6.3.4 Mexico Neoantigen Vaccine Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application
    7.1 Europe Neoantigen Vaccine Revenue by Type (2016-2026)
    7.2 Europe Neoantigen Vaccine Revenue by Application (2016-2026)
    7.3 Europe Neoantigen Vaccine Market Size by Country
        7.3.1 Europe Neoantigen Vaccine Revenue by Country (2016-2026)
        7.3.2 Germany Neoantigen Vaccine Market Size and Forecast (2016-2026)
        7.3.3 France Neoantigen Vaccine Market Size and Forecast (2016-2026)
        7.3.4 United Kingdom Neoantigen Vaccine Market Size and Forecast (2016-2026)
        7.3.5 Russia Neoantigen Vaccine Market Size and Forecast (2016-2026)
        7.3.6 Italy Neoantigen Vaccine Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application
    8.1 Asia-Pacific Neoantigen Vaccine Revenue by Type (2016-2026)
    8.2 Asia-Pacific Neoantigen Vaccine Revenue by Application (2016-2026)
    8.3 Asia-Pacific Neoantigen Vaccine Market Size by Region
        8.3.1 Asia-Pacific Neoantigen Vaccine Revenue by Region (2016-2026)
        8.3.2 China Neoantigen Vaccine Market Size and Forecast (2016-2026)
        8.3.3 Japan Neoantigen Vaccine Market Size and Forecast (2016-2026)
        8.3.4 South Korea Neoantigen Vaccine Market Size and Forecast (2016-2026)
        8.3.5 India Neoantigen Vaccine Market Size and Forecast (2016-2026)
        8.3.6 Southeast Asia Neoantigen Vaccine Market Size and Forecast (2016-2026)
        8.3.7 Australia Neoantigen Vaccine Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application
    9.1 South America Neoantigen Vaccine Revenue by Type (2016-2026)
    9.2 South America Neoantigen Vaccine Revenue by Application (2016-2026)
    9.3 South America Neoantigen Vaccine Market Size by Country
        9.3.1 South America Neoantigen Vaccine Revenue by Country (2016-2026)
        9.3.2 Brazil Neoantigen Vaccine Market Size and Forecast (2016-2026)
        9.3.3 Argentina Neoantigen Vaccine Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application
    10.1 Middle East & Africa Neoantigen Vaccine Revenue by Type (2016-2026)
    10.2 Middle East & Africa Neoantigen Vaccine Revenue by Application (2016-2026)
    10.3 Middle East & Africa Neoantigen Vaccine Market Size by Country
        10.3.1 Middle East & Africa Neoantigen Vaccine Revenue by Country (2016-2026)
        10.3.2 Turkey Neoantigen Vaccine Market Size and Forecast (2016-2026)
        10.3.3 Saudi Arabia Neoantigen Vaccine Market Size and Forecast (2016-2026)
        10.3.4 UAE Neoantigen Vaccine Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Neoantigen Vaccine Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
    Table 2. Global Neoantigen Vaccine Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
    Table 3. Global Market Neoantigen Vaccine Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
    Table 4. Global Neoantigen Vaccine Revenue (USD Million) by Region (2016-2021)
    Table 5. Global Neoantigen Vaccine Revenue Market Share by Region (2021-2026)
    Table 6. Pfizer Corporate Information, Head Office, and Major Competitors
    Table 7. Pfizer Major Business
    Table 8. Pfizer Neoantigen Vaccine Product and Solutions
    Table 9. Pfizer Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 10. Merck & Co Inc Corporate Information, Head Office, and Major Competitors
    Table 11. Merck & Co Inc Major Business
    Table 12. Merck & Co Inc Neoantigen Vaccine Product and Solutions
    Table 13. Merck & Co Inc Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 14. Eli Lilly and Company Corporate Information, Head Office, and Major Competitors
    Table 15. Eli Lilly and Company Major Business
    Table 16. Eli Lilly and Company Neoantigen Vaccine Product and Solutions
    Table 17. Eli Lilly and Company Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 18. BioNTech Corporate Information, Head Office, and Major Competitors
    Table 19. BioNTech Major Business
    Table 20. BioNTech Neoantigen Vaccine Product and Solutions
    Table 21. BioNTech Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 22. Roche Holding AG Corporate Information, Head Office, and Major Competitors
    Table 23. Roche Holding AG Major Business
    Table 24. Roche Holding AG Neoantigen Vaccine Product and Solutions
    Table 25. Roche Holding AG Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 26. OSE Immunotherapeutics Corporate Information, Head Office, and Major Competitors
    Table 27. OSE Immunotherapeutics Major Business
    Table 28. OSE Immunotherapeutics Neoantigen Vaccine Product and Solutions
    Table 29. OSE Immunotherapeutics Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 30. Gritstone Bio Corporate Information, Head Office, and Major Competitors
    Table 31. Gritstone Bio Major Business
    Table 32. Gritstone Bio Neoantigen Vaccine Product and Solutions
    Table 33. Gritstone Bio Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 34. Moderna Corporate Information, Head Office, and Major Competitors
    Table 35. Moderna Major Business
    Table 36. Moderna Neoantigen Vaccine Product and Solutions
    Table 37. Moderna Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 38. Avidea Technologies Corporate Information, Head Office, and Major Competitors
    Table 39. Avidea Technologies Major Business
    Table 40. Avidea Technologies Neoantigen Vaccine Product and Solutions
    Table 41. Avidea Technologies Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 42. Vaccibody AS Corporate Information, Head Office, and Major Competitors
    Table 43. Vaccibody AS Major Business
    Table 44. Vaccibody AS Neoantigen Vaccine Product and Solutions
    Table 45. Vaccibody AS Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 46. Agenus Inc Corporate Information, Head Office, and Major Competitors
    Table 47. Agenus Inc Major Business
    Table 48. Agenus Inc Neoantigen Vaccine Product and Solutions
    Table 49. Agenus Inc Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 50. Novogene Corporate Information, Head Office, and Major Competitors
    Table 51. Novogene Major Business
    Table 52. Novogene Neoantigen Vaccine Product and Solutions
    Table 53. Novogene Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 54. ZIOPHARM Oncology Corporate Information, Head Office, and Major Competitors
    Table 55. ZIOPHARM Oncology Major Business
    Table 56. ZIOPHARM Oncology Neoantigen Vaccine Product and Solutions
    Table 57. ZIOPHARM Oncology Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 58. ISA Pharmaceuticals Corporate Information, Head Office, and Major Competitors
    Table 59. ISA Pharmaceuticals Major Business
    Table 60. ISA Pharmaceuticals Neoantigen Vaccine Product and Solutions
    Table 61. ISA Pharmaceuticals Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 62. BrightPath Biotherapeutics Corporate Information, Head Office, and Major Competitors
    Table 63. BrightPath Biotherapeutics Major Business
    Table 64. BrightPath Biotherapeutics Neoantigen Vaccine Product and Solutions
    Table 65. BrightPath Biotherapeutics Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 66. Vaximm AG Corporate Information, Head Office, and Major Competitors
    Table 67. Vaximm AG Major Business
    Table 68. Vaximm AG Neoantigen Vaccine Product and Solutions
    Table 69. Vaximm AG Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 70. Medigene AG Corporate Information, Head Office, and Major Competitors
    Table 71. Medigene AG Major Business
    Table 72. Medigene AG Neoantigen Vaccine Product and Solutions
    Table 73. Medigene AG Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 74. Genocea Biosciences Inc Corporate Information, Head Office, and Major Competitors
    Table 75. Genocea Biosciences Inc Major Business
    Table 76. Genocea Biosciences Inc Neoantigen Vaccine Product and Solutions
    Table 77. Genocea Biosciences Inc Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 78. Advaxis Corporate Information, Head Office, and Major Competitors
    Table 79. Advaxis Major Business
    Table 80. Advaxis Neoantigen Vaccine Product and Solutions
    Table 81. Advaxis Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 82. Nouscom Corporate Information, Head Office, and Major Competitors
    Table 83. Nouscom Major Business
    Table 84. Nouscom Neoantigen Vaccine Product and Solutions
    Table 85. Nouscom Neoantigen Vaccine Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 86. Global Neoantigen Vaccine Revenue (USD Million) by Players (2019-2021)
    Table 87. Global Neoantigen Vaccine Revenue Share by Players (2019-2021)
    Table 88. Breakdown of Neoantigen Vaccine by Company Type (Tier 1, Tier 2 and Tier 3)
    Table 89. Neoantigen Vaccine Players Head Office, Products and Services Provided
    Table 90. Neoantigen Vaccine Mergers & Acquisitions in the Past Five Years
    Table 91. Neoantigen Vaccine New Entrants and Expansion Plans
    Table 92. Global Neoantigen Vaccine Revenue (USD Million) by Type (2016-2021)
    Table 93. Global Neoantigen Vaccine Revenue Share by Type (2016-2021)
    Table 94. Global Neoantigen Vaccine Revenue Forecast by Type (2021-2026)
    Table 95. Global Neoantigen Vaccine Revenue by Application (2016-2021)
    Table 96. Global Neoantigen Vaccine Revenue Forecast by Application (2021-2026)
    Table 97. North America Neoantigen Vaccine Revenue by Type (2016-2021) & (USD Million)
    Table 98. North America Neoantigen Vaccine Revenue by Type (2021-2026) & (USD Million)
    Table 99. North America Neoantigen Vaccine Revenue by Application (2016-2021) & (USD Million)
    Table 100. North America Neoantigen Vaccine Revenue by Application (2021-2026) & (USD Million)
    Table 101. North America Neoantigen Vaccine Revenue by Country (2016-2021) & (USD Million)
    Table 102. North America Neoantigen Vaccine Revenue by Country (2021-2026) & (USD Million)
    Table 103. Europe Neoantigen Vaccine Revenue by Type (2016-2021) & (USD Million)
    Table 104. Europe Neoantigen Vaccine Revenue by Type (2021-2026) & (USD Million)
    Table 105. Europe Neoantigen Vaccine Revenue by Application (2016-2021) & (USD Million)
    Table 106. Europe Neoantigen Vaccine Revenue by Application (2021-2026) & (USD Million)
    Table 107. Europe Neoantigen Vaccine Revenue by Country (2016-2021) & (USD Million)
    Table 108. Europe Neoantigen Vaccine Revenue by Country (2021-2026) & (USD Million)
    Table 109. Asia-Pacific Neoantigen Vaccine Revenue by Type (2016-2021) & (USD Million)
    Table 110. Asia-Pacific Neoantigen Vaccine Revenue by Type (2021-2026) & (USD Million)
    Table 111. Asia-Pacific Neoantigen Vaccine Revenue by Application (2016-2021) & (USD Million)
    Table 112. Asia-Pacific Neoantigen Vaccine Revenue by Application (2021-2026) & (USD Million)
    Table 113. Asia-Pacific Neoantigen Vaccine Revenue by Region (2016-2021) & (USD Million)
    Table 114. Asia-Pacific Neoantigen Vaccine Revenue by Region (2021-2026) & (USD Million)
    Table 115. South America Neoantigen Vaccine Revenue by Type (2016-2021) & (USD Million)
    Table 116. South America Neoantigen Vaccine Revenue by Type (2021-2026) & (USD Million)
    Table 117. South America Neoantigen Vaccine Revenue by Application (2016-2021) & (USD Million)
    Table 118. South America Neoantigen Vaccine Revenue by Application (2021-2026) & (USD Million)
    Table 119. South America Neoantigen Vaccine Revenue by Country (2016-2021) & (USD Million)
    Table 120. South America Neoantigen Vaccine Revenue by Country (2021-2026) & (USD Million)
    Table 121. Middle East & Africa Neoantigen Vaccine Revenue by Type (2016-2021) & (USD Million)
    Table 122. Middle East & Africa Neoantigen Vaccine Revenue by Type (2021-2026) & (USD Million)
    Table 123. Middle East & Africa Neoantigen Vaccine Revenue by Application (2016-2021) & (USD Million)
    Table 124. Middle East & Africa Neoantigen Vaccine Revenue by Application (2021-2026) & (USD Million)
    Table 125. Middle East & Africa Neoantigen Vaccine Revenue by Country (2016-2021) & (USD Million)
    Table 126. Middle East & Africa Neoantigen Vaccine Revenue by Country (2021-2026) & (USD Million)
List of Figures
    Figure 1. Neoantigen Vaccine Picture
    Figure 2. Global Neoantigen Vaccine Revenue Market Share by Type in 2020
    Figure 3. Personalized Vaccine
    Figure 4. Off-the shelf Vaccine
    Figure 5. Neoantigen Vaccine Revenue Market Share by Application in 2020
    Figure 6. Lung Cancer Picture
    Figure 7. Melanoma Cancer Picture
    Figure 8. Gastrointestinal Cancer Picture
    Figure 9. Brain Cancer Picture
    Figure 10. Others Picture
    Figure 11. Global Neoantigen Vaccine Revenue, (USD Million): 2020 VS 2021 VS 2026
    Figure 12. Global Neoantigen Vaccine Revenue and Forecast (2016-2026) & (USD Million)
    Figure 13. Global Neoantigen Vaccine Revenue Market Share by Region (2016-2026)
    Figure 14. Global Neoantigen Vaccine Revenue Market Share by Region in 2020
    Figure 15. North America Neoantigen Vaccine Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 16. Europe Neoantigen Vaccine Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 17. Asia-Pacific Neoantigen Vaccine Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 18. South America Neoantigen Vaccine Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 19. Middle East and Africa Neoantigen Vaccine Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 20. Neoantigen Vaccine Market Drivers
    Figure 21. Neoantigen Vaccine Market Restraints
    Figure 22. Neoantigen Vaccine Market Trends
    Figure 23. Pfizer Recent Developments and Future Plans
    Figure 24. Merck & Co Inc Recent Developments and Future Plans
    Figure 25. Eli Lilly and Company Recent Developments and Future Plans
    Figure 26. BioNTech Recent Developments and Future Plans
    Figure 27. Roche Holding AG Recent Developments and Future Plans
    Figure 28. OSE Immunotherapeutics Recent Developments and Future Plans
    Figure 29. Gritstone Bio Recent Developments and Future Plans
    Figure 30. Moderna Recent Developments and Future Plans
    Figure 31. Avidea Technologies Recent Developments and Future Plans
    Figure 32. Vaccibody AS Recent Developments and Future Plans
    Figure 33. Agenus Inc Recent Developments and Future Plans
    Figure 34. Novogene Recent Developments and Future Plans
    Figure 35. ZIOPHARM Oncology Recent Developments and Future Plans
    Figure 36. ISA Pharmaceuticals Recent Developments and Future Plans
    Figure 37. BrightPath Biotherapeutics Recent Developments and Future Plans
    Figure 38. Vaximm AG Recent Developments and Future Plans
    Figure 39. Medigene AG Recent Developments and Future Plans
    Figure 40. Genocea Biosciences Inc Recent Developments and Future Plans
    Figure 41. Advaxis Recent Developments and Future Plans
    Figure 42. Nouscom Recent Developments and Future Plans
    Figure 43. Global Neoantigen Vaccine Revenue Share by Players in 2020
    Figure 44. Neoantigen Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    Figure 45. Global Top 3 Players Neoantigen Vaccine Revenue Market Share in 2020
    Figure 46. Global Top 10 Players Neoantigen Vaccine Revenue Market Share in 2020
    Figure 47. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
    Figure 48. Global Neoantigen Vaccine Revenue Share by Type in 2020
    Figure 49. Global Neoantigen Vaccine Market Share Forecast by Type (2021-2026)
    Figure 50. Global Neoantigen Vaccine Revenue Share by Application in 2020
    Figure 51. Global Neoantigen Vaccine Market Share Forecast by Application (2021-2026)
    Figure 52. North America Neoantigen Vaccine Sales Market Share by Type (2016-2026)
    Figure 53. North America Neoantigen Vaccine Sales Market Share by Application (2016-2026)
    Figure 54. North America Neoantigen Vaccine Revenue Market Share by Country (2016-2026)
    Figure 55. United States Neoantigen Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 56. Canada Neoantigen Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 57. Mexico Neoantigen Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 58. Europe Neoantigen Vaccine Sales Market Share by Type (2016-2026)
    Figure 59. Europe Neoantigen Vaccine Sales Market Share by Application (2016-2026)
    Figure 60. Europe Neoantigen Vaccine Revenue Market Share by Country (2016-2026)
    Figure 61. Germany Neoantigen Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 62. France Neoantigen Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 63. United Kingdom Neoantigen Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 64. Russia Neoantigen Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 65. Italy Neoantigen Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 66. Asia-Pacific Neoantigen Vaccine Sales Market Share by Type (2016-2026)
    Figure 67. Asia-Pacific Neoantigen Vaccine Sales Market Share by Application (2016-2026)
    Figure 68. Asia-Pacific Neoantigen Vaccine Revenue Market Share by Region (2016-2026)
    Figure 69. China Neoantigen Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 70. Japan Neoantigen Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 71. South Korea Neoantigen Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 72. India Neoantigen Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 73. Southeast Asia Neoantigen Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 74. Australia Neoantigen Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 75. South America Neoantigen Vaccine Sales Market Share by Type (2016-2026)
    Figure 76. South America Neoantigen Vaccine Sales Market Share by Application (2016-2026)
    Figure 77. South America Neoantigen Vaccine Revenue Market Share by Country (2016-2026)
    Figure 78. Brazil Neoantigen Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 79. Argentina Neoantigen Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 80. Middle East and Africa Neoantigen Vaccine Sales Market Share by Type (2016-2026)
    Figure 81. Middle East and Africa Neoantigen Vaccine Sales Market Share by Application (2016-2026)
    Figure 82. Middle East and Africa Neoantigen Vaccine Revenue Market Share by Country (2016-2026)
    Figure 83. Turkey Neoantigen Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 84. Saudi Arabia Neoantigen Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 85. UAE Neoantigen Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 86. Methodology
    Figure 87. Research Process and Data Source

Companies Mentioned

Pfizer
Merck & Co Inc
Eli Lilly and Company
BioNTech
Roche Holding AG
OSE Immunotherapeutics
Gritstone Bio
Moderna
Avidea Technologies
Vaccibody AS
Agenus Inc
Novogene
ZIOPHARM Oncology
ISA Pharmaceuticals
BrightPath Biotherapeutics
Vaximm AG
Medigene AG
Genocea Biosciences Inc
Advaxis
Nouscom